Cargando…

Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study

BACKGROUND: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatment for inflammatory rheumatic diseases, medication adherence to DMARDs is often suboptimal. Effective interventions to improve adherence to DMARDs are lacking, and new targets are needed to improve adh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voshaar, Marieke, Vriezekolk, Johanna, van Dulmen, Sandra, van den Bemt, Bart, van de Laar, Mart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075197/ https://www.ncbi.nlm.nih.gov/pubmed/27769224 http://dx.doi.org/10.1186/s12891-016-1289-z

Ejemplares similares

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping
por: Pouls, Bart PH, et al.
Publicado: (2022)

Ranking facilitators and barriers of medication adherence by patients with inflammatory arthritis: a maximum difference scaling exercise
por: Voshaar, M. J. H., et al.
Publicado: (2021)

A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement, and selection of attributes and levels
por: Mathijssen, Elke GE, et al.
Publicado: (2018)

Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence
por: van Heuckelum, M., et al.
Publicado: (2019)

Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease
por: Pasma, Annelieke, et al.
Publicado: (2015)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
por: van Heuckelum, Milou, et al.
Publicado: (2019)

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
por: Van De Laar, Celine J, et al.
Publicado: (2020)

Psychosocial predictors of non-adherence to chronic medication: systematic review of longitudinal studies
por: Zwikker, Hanneke E, et al.
Publicado: (2014)

The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence
por: Geurts-Voerman, Gerlienke E., et al.
Publicado: (2020)

Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
por: Nota, Ingrid, et al.
Publicado: (2014)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
por: Nota, Ingrid, et al.
Publicado: (2016)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Effect of Interactive eHealth Interventions on Improving Medication Adherence in Adults With Long-Term Medication: Systematic Review
por: Pouls, Bart P H, et al.
Publicado: (2021)

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
por: Kemper, Alex R, et al.
Publicado: (2012)

Drug-related problems reported by patients with rheumatic diseases: an observational study
por: Haegens, Lex L., et al.
Publicado: (2023)

Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis
por: Mathijssen, Elke GE, et al.
Publicado: (2018)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Application of the health assessment questionnaire disability index to various rheumatic diseases
por: van Groen, Maaike M., et al.
Publicado: (2010)

Spectrum of infections occurring in patients of autoimmune rheumatic diseases on treatment with biological versus conventional disease-modifying antirheumatic drugs: A comparative study
por: Gupta, Partisha, et al.
Publicado: (2022)

Exploring healthcare professionals’ knowledge, attitudes and experiences of shared decision making in rheumatology
por: Mathijssen, Elke G E, et al.
Publicado: (2020)

Stem cell transplantation for rheumatic autoimmune diseases
por: Hügle, Thomas, et al.
Publicado: (2008)

Factors Influencing Preferences of Patients With Rheumatic Diseases Regarding Telehealth Channels for Support With Medication Use: Qualitative Study
por: Haegens, Lex L, et al.
Publicado: (2023)

Gaming for Adherence to Medication using Ehealth in Rheumatoid arthritis (GAMER) study: a randomised controlled trial
por: Pouls, Bart P H, et al.
Publicado: (2022)

VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs
por: Schub, David, et al.
Publicado: (2018)

Two parallel short forms to measure disease- and treatment-associated knowledge in rheumatoid arthritis: application of item response theory
por: Spijk-de Jonge, Marieke J, et al.
Publicado: (2020)

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
por: Andreica, Ioana, et al.
Publicado: (2022)

Allogeneic stem cell transplantation for rheumatic autoimmune diseases
por: Hügle, Thomas, et al.
Publicado: (2010)

Beliefs of rheumatologists and general practitioners on urate lowering therapy: a cross-sectional study
por: Veenstra, Frouwke, et al.
Publicado: (2023)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
por: van Vollenhoven, Ronald, et al.
Publicado: (2018)

Improving Knowledge of Lactation Compatibility of Antirheumatic Medications Among Providers Who Care for Patients With Rheumatic Disease
por: Mills, Brooke S., et al.
Publicado: (2021)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Barriers and facilitators for the usage of a personal health record for medication reconciliation: A qualitative study among patients
por: van der Nat, Denise J., et al.
Publicado: (2022)

Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods
por: Nota, Ingrid, et al.
Publicado: (2017)

Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider
por: Ritschl, Valentin, et al.
Publicado: (2020)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

Gold Finger: Metal Jewellery as a Disease Modifying Antirheumatic Therapy!
por: Hlaing, T., et al.
Publicado: (2009)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Frequency and trends of disease‐modifying antirheumatic drug (DMARD) use in Germany
por: Fassmer, Alexander M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_725vbkpe17bkqof5jvos3k2a0k